君實生物-B(01877.HK)與杭州多禧簽署藥品開發合同進一步豐富藥物研發管線
格隆匯12月3日丨君實生物-B(01877.HK)公佈,公司與杭州多禧生物科技有限公司簽署了《藥品開發及許可合同》。根據協議約定,公司通過獨佔許可授權方式從杭州多禧處獲得許可使用DAC-002(注射用重組人源化抗Trop2單抗-Tub196偶聯劑),在授權許可區域(除日本、韓國以外的全部亞洲國家及區域)內負責DAC-002後續的臨牀試驗、藥品註冊、商業化生產、銷售及其他商業活動。
根據該協議,杭州多禧將獲得3,000萬元人民幣的首付款和226.8萬元人民幣的樣品製備費用,從DAC-002在許可區域內獲批臨牀至獲批上市,公司將按研發進展向杭州多禧支付累計不超過2.7億元人民幣的研發及上市裏程碑款,並在DAC-002實現商業化銷售後向杭州多禧支付年銷售收入6%-10%的收益分成。
據悉,DAC-002是抗Trop2單抗通過智能連結體偶聯抗微管蛋白TubulysinB類似物的藥物,主要用於治療Trop2陽性三陰性乳腺癌、小細胞肺癌、胰腺癌等實體腫瘤,目前已向國家藥品監督管理局申報臨牀試驗並獲受理。
杭州多禧位於浙江省杭州市經濟技術開發區,專注於研發靶向治療癌症的單克隆抗體藥物共軛體系列生物新藥。本公司目前持有杭州多禧約4.5479%的股份。
公司稱,協議的簽署符合公司發展的需要,將進一步豐富該公司藥物的研發管線,且預期將對該公司的持續經營產生積極影響。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.